Latest News and Press Releases

Reported positive clinical proof-of-concept data for OD-001 in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis.

Odyssey Therapeutics, Inc. announces pricing of its upsized IPO of 15,500,000 shares of its common stock at an IPO price of $18 per share.